XXXX in lower @entity1729 --a comparison with @entity115 .

@entity1 @entity115 @entity1729 @entity158 @entity800
This study aimed at determining the clinical efficacy and clinical and biological safety of @entity800 compared to @entity115 . 44 @entity1 were included, and 41 were evaluable. 33 @entity1 were treated according to the randomization list, whereas 11 @entity1 were treated in an open study. All @entity1 were suffering from acute, recurrent or chronic, lower @entity1729 . 29 @entity1 started @entity800 treatment with a dosage of 200 mg or 300 mg b.i.d., and 15 other @entity1 received 1 g @entity115 b.i.d. or t.i.d. Three @entity1 of this last group were treated with @entity800 after @entity115 treatment failure. Bacteriological eradication was achieved in 95% of @entity800 -treated and in 78% of @entity115 -treated @entity1 . Clinical cure occurred in 86% of @entity800 - and in 55% of @entity115 -treated @entity1 . Successful treatment (bacteriologic eradication associated with clinical cure) was observed in 75% of @entity1 from the @entity800 -group and in 36% of the @entity115 -group. No clinical adverse reactions were seen in @entity115 -treated @entity1 , whereas one @entity1 in the @entity800 -group was complaining of mild, definitely drug-related, @entity158 . No major drug-related disturbances of biological parameters were observed neither in the @entity800 - nor in the @entity115 -group.
